Skip to main content

Table 3 Cox model analysis for 87 ESCC patients with locoregional recurrence before matching

From: Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis

Variable n Univariate Multivariate
HR 95%CI P HR 95%CI P
Age (years)
  < 65/≥65 58/29 0.786 0.467–1.322 0.364    
KPS
 70–80/>80 32/55 0.752 0.467–1.212 0.243    
Gender
 Male/Female 65/22 1.008 0.607–1.673 0.976    
Smoking
 Yes/No 31/56 1.438 0.893–2.317 0.135    
Alcohol consumption
 Yes/No 15/72 1.229 0.668–2.261 0.507    
Primary tumor location
 Upper/Middle and lower thoracic 34/53 1.241 0.779–1.977 0.364    
Clinical stage
 I + II/III 26/61 1.083 0.645–1.820 0.763 1.027 0.599–1.761 0.923
Surgery in the initial treatment
 Yes/No 11/76 1.161 0.608–2.216 0.652    
Chemotherapy in the initial treatment
 Yes/No 43/44 0.954 0.601–1.514 0.842    
Recurrence-free interval (months)
 ≤12/> 12 38/49 0.884 0.558–1.402 0.601    
Pattern of recurrence
 LN/PF 14/73 0.385 0.195–0.762 0.006 0.461 0.221–0.964 0.040
Re-RT after recurrence
 Yes/No 39/48 0.392 0.239–0.642 < 0.001 0.513 0.299–0.878 0.015
Chemotherapy after recurrence
 Yes/No 26/61 0.799 0.478–1.335 0.391    
Chemotherapy for both course treatment
 Yes/No 13/74 0.540 0.274–1.063 0.074 0.520 0.257–1.051 0.069
  1. Abbreviations: HR Hazard ratio, 95%CI 95% confidence interval, Re-RT Re-irradiation, LN Regional lymph node recurrence only, PF Primary failure with/without regional lymph node recurrence, KPS Karnofsky performance status